Discounted Cash Flow Rating

Return on Equity Rating

Debt to Equity Rating

Price to Earnings Rating

Analyst Rating

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Strong Sell

D

VanEck Dynamic High Income ETF (INC)

No description provided.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/03/2022

Market Cap

818,480

Shares Outstanding

30,000

Weighted SO

N/A

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

CORP --.--%

CO --.--%

COM --.--%

FUND --.--%

HIGH --.--%

Beta

0.6294

Last Div

1.5405

Range

24.26-27.22

Chg

0.5428

Avg Vol

301

Mkt Cap

818480

Exch

AMEX

Country

US

Phone

NA

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0568

P/S

N/A

EV Multiple

N/A

P/FV

N/A

Div Yield %

5.6846

P/E

N/A

PEG

N/A

Payout

N/A

Current Ratio

N/A

Quick Ratio

N/A

Cash Ratio

N/A

DSO

N/A

DIO

N/A

Op Cycle

N/A

DPO

N/A

CCC

N/A

Gross Margin

N/A

Op Margin

N/A

Pretax Margin

N/A

Net Margin

N/A

Eff Tax Rate

N/A

ROA

N/A

ROE

N/A

ROCE

N/A

NI/EBT

N/A

EBT/EBIT

N/A

EBIT/Rev

N/A

Debt Ratio

N/A

D/E

N/A

LT Debt/Cap

N/A

Total Debt/Cap

N/A

Int Coverage

N/A

CF/Debt

N/A

Equity Multi

N/A

Rec Turnover

N/A

Pay Turnover

N/A

Inv Turnover

N/A

FA Turnover

N/A

Asset Turnover

N/A

OCF/Share

N/A

FCF/Share

N/A

Cash/Share

N/A

OCF/Sales

N/A

FCF/OCF

N/A

CF Coverage

N/A

ST Coverage

N/A

CapEx Coverage

N/A

Div&CapEx Cov

N/A

P/BV

N/A

P/B

N/A

P/S

N/A

P/E

N/A

P/FCF

N/A

P/OCF

N/A

P/CF

N/A

PEG

N/A

P/S

N/A

EV Multiple

N/A

P/FV

N/A

DPS

1.5405

Latest Headlines (EST)

GlobeNewswire Inc. Jan 02, 22:30 $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – VINC, VCSA, MRNS, MHLD GlobeNewswire Inc. Sep 26, 00:26 Lincoln Tech Launches HVAC and Electrical Career Training at Moorestown, NJ Campus GlobeNewswire Inc. Sep 22, 04:30 Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight GlobeNewswire Inc. Aug 23, 22:19 Lincoln Educational Services to Provide Business Overview and Highlight Growth Strategy at Midwest IDEAS Conference Zacks Investment Research Jun 11, 00:00 India ETF (INCO) Hits New 52-Week High Benzinga Jan 10, 15:12 Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations MarketWatch Jan 09, 09:13 Here are Wall Street’s favorite stocks in the sector expected to grow profits the most in 2024 GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma MarketWatch Jan 06, 05:49 ‘The ETF is winning out long term’: BlackRock tops market share for ETFs, but 2023 flows point to Vanguard catching up

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.18 07/01/2024 12/13/2023 07/01/2024 07/05/2024
0.19 06/03/2024 12/13/2023 06/03/2024 06/06/2024
0.10 04/23/2024 12/13/2023 04/24/2024 04/29/2024
0.17 04/01/2024 11/30/-0001 11/30/-0001 11/30/-0001
0.07 03/01/2024 12/13/2023 03/04/2024 03/07/2024
0.09 02/01/2024 12/13/2023 02/02/2024 02/07/2024
0.22 12/27/2023 12/07/2022 12/28/2023 12/29/2023
0.07 12/01/2023 12/07/2022 12/04/2023 12/07/2023
0.08 11/01/2023 12/07/2022 11/02/2023 11/07/2023
0.20 10/02/2023 12/07/2022 10/03/2023 10/06/2023
0.08 09/01/2023 12/07/2022 09/05/2023 09/08/2023
0.10 08/01/2023 12/07/2022 08/02/2023 08/10/2023
0.19 07/03/2023 12/07/2022 07/05/2023 07/07/2023
0.12 06/01/2023 05/31/2023 06/02/2023 06/07/2023
0.06 04/24/2023 12/07/2022 04/25/2023 04/28/2023
0.18 04/03/2023 11/30/-0001 04/04/2023 04/10/2023
0.09 03/01/2023 12/07/2022 03/02/2023 03/07/2023
0.08 02/01/2023 12/07/2022 02/02/2023 02/07/2023
0.18 12/28/2022 12/27/2022 12/29/2022 12/30/2022
0.08 12/01/2022 11/30/2022 12/02/2022 12/07/2022